Trial Profile
A Phase I Study of Pyrotinib In Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Pyrotinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jun 2022 Results of pooled analysis from (NCT01937689,NCT02361112,NCT02422199,NCT03080805) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 28 May 2019 Results (Data cut off, 31 Jan 2018)assessing safety, efficacy and biomarker Analysis of Pyrotinib in combination with capecitabine, published in the Clinical Cancer Research